Invasive ductal carcinoma of the breast with the "triple- negative" phenotype: Prognostic implications of EGFR immunoreactivity

Breast Cancer Research and Treatment

Volumn 116, Issue 2, 2009, Pages 317-328

  Viale, Giuseppe ^a,b   Rotmensz, Nicole ^a   Maisonneuve, Patrick ^a   Bottiglieri, Luca ^a   Montagna, Emilia ^a   Luini, Alberto ^a   Veronesi, Paolo ^a,b   Intra, Mattia ^a   Torrisi, Rosalba ^a   Cardillo, Anna ^a   Campagnoli, Elisabetta ^a   Goldhirsch, Aron ^a   Colleoni, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Adjuvant treatment; Breast cancer; EGFR; Triple negative

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SENTINEL LYMPH NODE BIOPSY;

AGE FACTORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MASTECTOMY; PHENOTYPE; PROGNOSIS; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SENTINEL LYMPH NODE BIOPSY; TUMOR MARKERS, BIOLOGICAL;

EID: 67649211199     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0206-z     Document Type: Article

References (46)

1. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752. doi:10.1038/350 21093
2. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874. doi:10.1073/pnas.191367098
3. Yehiely F, Moyano JV, Evans JR et al (2006) Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 12:537-544. doi:10.1016/j.molmed.2006.09.004
4. Abd El-Rehim DM, Pinder SE, Paish CE et al (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203:661-671. doi:10.1002/path.1559
5. Livasy CA, Karaca G, Nanda R et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264-271. doi:10.1038/modpathol.3800528
6. Abd El-Rehim DM, Ball G, Pinder SE et al (2005) Highthroughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340-350. doi:10.1002/ijc. 21004
7. Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25-32. doi: 10.1002/cncr.22381
8. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434. doi:10.1158/1078-0432.CCR-06- 3045
9. Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374. doi:10.1158/ 1078-0432.CCR-04-0220
10. McShane LM, Altman DG, Sauerbrei W et al (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229-235. doi:10.1007/ s10549-006-9242-8
11. Japaze H, Emina J, Diaz C, Schwam RJ et al (2005) 'Pure' invasive apocrine carcinoma of the breast: a new clinicopathological entity? Breast 14:3-10. doi:10.1016/j.breast.2004.06.003
12. Azoulay S, Lae' M, Fre'neaux P, Merle S et al (2005) KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol 8:1623-1631
13. Orlando L, Renne G, Rocca A et al (2005) Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. Ann Oncol 16:1094-1099. doi:10.1093/annonc/mdi213
14. Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546-553. doi: 10.1056/NEJMoa012782
15. Gennari R, Curigliano G, Rotmensz N et al (2004) Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. Cancer 101:1302-1310. doi:10.1002/cncr. 20535
16. Goldhirsch A, Wood WC, Senn HJ et al (1995) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87:1441-1445. doi:10.1093/jnci/ 87.19.1441
17. Goldhirsch A, Glick JH, Gelber RD et al (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601-1608. doi:10.1093/jnci/ 90.21.1601
18. Colleoni M, Liman HJ, Castiglione-Gertsch M et al (2002) Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 86:1705-1714. doi:10.1038/sj. bjc.6600334
19. Fisher B, Brown AM, Dimitrov NV et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B 15. J Clin Oncol 8:1483-1496
20. Levine MN, Bramwell VH, Pritchard KL et al (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 16:2651-2658
21. Veronesi U, Paganelli G, Galimberti V et al (1997) Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 349:1864-1867. doi:10.1016/ S0140-6736(97)01004-0
22. Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C Histopathology 41(3A):154-161. doi:10.1046/j.1365-2559.2002.14691.x
23. Rosen PP, Oberman H (1993) Tumors of the mammary gland. Armed Forces Institute of Pathology, Washington, DC
24. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S (2000) Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 24:197-202. doi:10.1097/00000478-200002000- 00005
25. Colleoni M, Orvieto E, Nole F et al (1999) Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 35:574-579. doi:10.1016/S0959-8049(99)00005-2
26. Banerjee S, Reis-Filho JS, Ashley S et al (2006) Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59:729-735. doi:10.1136/jcp.2005.033043
27. Ribeiro-Silva A, Ramalho LN, Garcia SB et al (2005) p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 47:458-466. doi: 10.1111/j.1365-2559.2005.02249.x
28. Cleator S, Heller W, Coombes RC et al (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235-244. doi: 10.1016/S1470-2045(07) 70074-8
29. Goldhirsch A, Wood WC, Gelber RD (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133- 1144. doi:10.1093/annonc/mdm271
30. Nieto Y, Nawaz F, Jones RB et al (2007) Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol 25:4405- 4413. doi:10.1200/JCO.2006.09.8822
31. Cheang MCU, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368-1376. doi:10.1158/1078-0432.CCR-07-1658
32. Guix M, s Granja N, Meszoely I et al (2008) Short preoperative treatment with Erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancer. J Clin Oncol 26:897-906. doi:10.1200/JCO.2007.13.5939
33. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18
34. Stendahl M, Ryden L, Nordenskjold B (2006) High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12:4614-4618. doi:10.1158/1078-0432.CCR- 06-0248
35. Khalifa MA, Rowsell CH, Gladdy RA, Ko YJ, Hanna S, Smith A et al (2006) Expression of epidermal growth factor receptor in primary colorectal adenocarcinoma predicts expression in recurrent disease. Am J Clin Pathol 125:229-233
36. Hirsch FR, Dziadzuszko R, Thatcher N et al (2008) Epidermal growth factor receptor immunohistochemistry. Cancer 112:1114- 1121. doi:10.1002/cncr.23282
37. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al (2003) Epidermal growth factor receptor in non-small cell lung cancer carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 1521:3798-3807
38. Torrisi R, Rotmensz N, Bagnardi V et al (2007) HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 43:2339-2344. doi: 10.1016/j.ejca.2007.07.033
39. Dellapasqua S, Colleoni M, CastiglioneMet al (2007) New criteria for selecting elderly patients for breast cancer adjuvant treatment studies. Oncologist 12:952-959. doi:10.1634/theoncologist.12-8- 952
40. Colleoni M, Rotmensz N, Maisonneuve P et al (2007) Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol 18:1632-1640. doi:10.1093/annonc/ mdm268
41. Van de Rijn M, Perou CM, Tibshirani R et al (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161:1991-1996
42. Jumppanen M, Gruvberger-Saal S, Kauraniemi P et al (2007) Basal like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 9:R16. doi:10.1186/bcr1649
43. Colpaert C, Vermeulen P, Jeuris W et al (2001) Early distant relapse in ''node-negative'' breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumours. J Pathol 193:442-449. doi:10.1002/path.829
44. Fulford LG, Easton DF, Reis-Filho JS et al (2006) Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49:22-34. doi:10.1111/j.1365-2559.2006.02453.x
45. Putti TC, El-Rehim DM, Rakha EA et al (2005) Estrogen receptornegative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18:26-35. doi:10.1038/ modpathol.3800255
46. Siziopikou KP, Cobleigh M (2007) The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 16:104-107. doi: 10.1016/j.breast.2006.09.003